Atrasentan Achieves Positive Topline Results in Phase 3 Trial for IgA Nephropathy
Atrasentan demonstrated superiority versus placebo for reduction in proteinuria through 36 weeks.
Shreeram Aradhye Novartis Shreeram Aradhye Chinook Therapeutics Immunoglobin A Iga Nephropathy Phase 3
Source: hcplive.com